ACASTI PHARMA INC (ACST) Stock Price, Quote, News and Overview
NASDAQ:ACST - Nasdaq - CA00430K8656 - Common Stock - Currency: USD
ACST Quote, Performance and Key Statistics
3.37
-0.03 (-0.88%)
The current stock price of ACST is 3.37 USD. In the past month the price increased by 8.01%. In the past year, price increased by 40.42%.
ACST Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ACST
Company Profile
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The company is headquartered in Laval, Quebec. The company went IPO on 2013-03-07. The firm is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Company Info
ACASTI PHARMA INC
3009, Boul. De La Concorde East, Suite 102
Laval QUEBEC H7E 2B5 CA
CEO: Jan D'Alvise
Employees: 32
Company Website: https://www.acasti.com/en
Phone: 14506864555
ACASTI PHARMA INC / ACST FAQ
What is the stock price of ACASTI PHARMA INC today?
The current stock price of ACST is 3.37 USD. The price decreased by -0.88% in the last trading session.
What is the ticker symbol for ACASTI PHARMA INC stock?
The exchange symbol of ACASTI PHARMA INC is ACST and it is listed on the Nasdaq exchange.
On which exchange is ACST stock listed?
ACST stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACASTI PHARMA INC stock?
7 analysts have analysed ACST and the average price target is 8.16 USD. This implies a price increase of 142.14% is expected in the next year compared to the current price of 3.37. Check the ACASTI PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACASTI PHARMA INC worth?
ACASTI PHARMA INC (ACST) has a market capitalization of 34.17M USD. This makes ACST a Nano Cap stock.
How many employees does ACASTI PHARMA INC have?
ACASTI PHARMA INC (ACST) currently has 32 employees.
What are the support and resistance levels for ACASTI PHARMA INC (ACST) stock?
ACASTI PHARMA INC (ACST) has a support level at 3.24 and a resistance level at 3.38. Check the full technical report for a detailed analysis of ACST support and resistance levels.
Should I buy ACASTI PHARMA INC (ACST) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACST, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACST, evaluating the profitability, health, valuation and growth aspects
- ACASTI PHARMA INC (ACST) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACASTI PHARMA INC (ACST) Sales and EPS estimates to see what analysts future expectations are.
- ACASTI PHARMA INC (ACST) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACASTI PHARMA INC (ACST) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACASTI PHARMA INC (ACST) Stock Chart to make your own analysis
- ACASTI PHARMA INC (ACST) Latest news and press-releases to stay up to date.
Does ACASTI PHARMA INC (ACST) stock pay dividends?
ACST does not pay a dividend.
When does ACASTI PHARMA INC (ACST) report earnings?
ACASTI PHARMA INC (ACST) will report earnings on 2024-11-11, before the market open.
What is the Price/Earnings (PE) ratio of ACASTI PHARMA INC (ACST)?
ACASTI PHARMA INC (ACST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.04).
ACST Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ACST. When comparing the yearly performance of all stocks, ACST is one of the better performing stocks in the market, outperforming 86.9% of all stocks.
ACST Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACST. No worries on liquidiy or solvency for ACST as it has an excellent financial health rating, but there are worries on the profitability.
ACST Financial Highlights
Over the last trailing twelve months ACST reported a non-GAAP Earnings per Share(EPS) of -1.04. The EPS increased by 78.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.41% | ||
| ROE | -19.28% | ||
| Debt/Equity | 0 |
ACST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ACST. The Buy consensus is the average rating of analysts ratings from 7 analysts.